search icon
      blog search icon

      MDXG Stock: MiMedx Gains on Analyst Endorsement

      By Fahim Awan

      Published on

      October 30, 2023

      7:01 AM UTC

      MDXG Stock: MiMedx Gains on Analyst Endorsement

      MiMedx Group, Inc. (NASDAQ: MDXG) shares exhibited an increase of 0.33%, closing at $6.15 in the regular trading session on Friday. The stock’s upward trajectory on the recent charts can be attributed to a notable endorsement by an analyst firm today.

      Craig-Hallum has commenced coverage of MiMedx (MDXG) with an enthusiastic Buy rating and a substantial $12 price target, as articulated in a communication to investors, bearing the headline “MiMedx Is Poised to Ascend as the Definitive Wound Care Company.”

      The rationale behind this positive outlook stems from recent shifts in management and the company’s strategic pivot back to its core wound care business, away from other ventures, all of which positions MiMedx to deliver considerable value to its shareholders, according to the analyst firm.

      MiMedx has recently introduced its latest addition to the array of Advanced Wound Care (AWC) solutions, known as EPIEFFECT. This innovative solution extends the core AWC offerings by MDXG, catering to medical professionals who treat challenging, slow-to-heal wounds, including conditions like diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).

      EPIEFFECT boasts a robust, three-layer structure, which lends itself well to securely affixing grafts with sutures. Additionally, its attributes and handling characteristics render it a preferred option for addressing deep or tunneling wounds. EPIEFFECT represents a robust, tri-layer choice for our clientele, including those within the private physician office domain.

      MiMedx adheres to a strategic approach aimed at delivering the most clinically effective and evidence-based products, meticulously tailored to meet specific demands and use cases within the markets it serves. MDXG firmly believes that EPIEFFECT adeptly fulfills the demand for a comprehensive allograft solution, offered in a variety of sizes, capable of addressing intricate wounds in an outpatient setting, preempting the need for hospital-based interventions.

      Additionally, MiMedx is slated to unveil its operating and financial results for the third quarter, concluding on September 30, 2023, subsequent to the close of the market on Monday, October 30, 2023. The senior management team at MiMedx will conduct a webcast and conference call at 4:30 p.m. Eastern Time on the same day to comprehensively review these results.

      More From Stocks telegraph